5'H-spiro[piperidine-4,4'-pyrrolo[1,2-a]quinoxaline] | 59474-46-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 5'H-spiro[piperidine-4,4'-pyrrolo[1,2-a]quinoxaline]
• 英文别名: 5'H-Spiro[piperidine-4,4'-pyrrolo[1,2-A]quinoxaline]；spiro[5H-pyrrolo[1,2-a]quinoxaline-4,4'-piperidine]
• CAS: 59474-46-3
• 化学式: C₁₅H₁₇N₃
• mdl: MFCD16991820
• 分子量: 239.32
• InChiKey: MAKYMFRXPNRPPO-UHFFFAOYSA-N

物化性质

• 沸点：
  442.5±45.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  29
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,5-二甲基苯甲酸 、 5'H-spiro[piperidine-4,4'-pyrrolo[1,2-a]quinoxaline] 在 4-二甲氨基吡啶 、 N-羟基-7-氮杂苯并三氮唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 (3,5-dimethylphenyl)-spiro[5H-pyrrolo[1,2-a]quinoxaline-4,4'-piperidine]-1'-ylmethanone
  参考文献：
  名称：

  Discovery of pyrrolo-benzo-1,4-diazines as potent Nav1.7 sodium channel blockers

  摘要：

  A series of pyrrolo-benzo-1,4-diazine analogs have been synthesized and displayed potent Nav1.7 inhibitory activity and moderate selectivity over Nav1.5. The syntheses, structure-activity relationships, and selected pharmacokinetic data of these analogs are described. Compound 41 displayed anti-nociceptive efficacy in the rat CFA pain model at 100 mpk oral dosing.

  DOI：

  10.1016/j.bmcl.2014.07.060
• 作为产物：
  描述：

  1-(2-硝基苯基)吡咯 在 bismuth(III) chloride 、 sodium tetrahydroborate 、 顺丁烯二酸 作用下， 以 乙醇 为溶剂， 生成 5'H-spiro[piperidine-4,4'-pyrrolo[1,2-a]quinoxaline]
  参考文献：
  名称：

  Discovery of pyrrolo-benzo-1,4-diazines as potent Nav1.7 sodium channel blockers

  摘要：

  A series of pyrrolo-benzo-1,4-diazine analogs have been synthesized and displayed potent Nav1.7 inhibitory activity and moderate selectivity over Nav1.5. The syntheses, structure-activity relationships, and selected pharmacokinetic data of these analogs are described. Compound 41 displayed anti-nociceptive efficacy in the rat CFA pain model at 100 mpk oral dosing.

  DOI：

  10.1016/j.bmcl.2014.07.060

文献信息

• [EN] PYRROLO-BENZO-1,4-DIAZINES USEFUL AS SODIUM CHANNEL BLOCKERS<br/>[FR] PYRROLO-BENZO-1,4-DIAZINES UTILES EN TANT QUE BLOQUEURS DE CANAUX SODIQUES
  申请人：SCHERING CORP

  公开号：WO2010151595A1

  公开（公告）日：2010-12-29

  Pyrrolo-benzo-1,4-diazine compounds represented by Formula I or II, or pharmaceutically acceptable salts thereof, are blockers of voltage-gated sodium channels. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, voltage-gated sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy or epilepsy conditions, irritable bowel syndrome, depression, anxiety, bipolar disorder, neurodegenerative disorders, psychiatric disorders, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, neuropathy and tinnitus, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.

  由公式I或II表示的吡咯-苯并-1,4-二嗪化合物或其药学上可接受的盐是电压门控钠通道的阻滞剂。药物组合物包括即时化合物的有效量，可以单独使用，也可以与一个或多个其他治疗活性化合物结合，并且包含药学上可接受的载体。治疗与电压门控钠通道活性相关或由此引起的疾病的方法，包括例如急性疼痛、慢性疼痛、内脏疼痛、炎症性疼痛、神经病性疼痛、癫痫或癫痫症状、肠易激综合征、抑郁症、焦虑症、躁郁症、神经退行性疾病、精神疾病、肌张力过高、心律失常、运动障碍、神经内分泌失调、共济失调、多发性硬化、肠易激综合征、尿失禁、神经病和耳鸣，包括单独或与一个或多个其他治疗活性化合物结合的即时化合物的有效量。
• COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILISATION
  申请人：Oniciu Daniela Carmen

  公开号：US20120129856A1

  公开（公告）日：2012-05-24

  The invention relates to classes of pharmaceutically-active heterocyclic compounds and pharmaceutically acceptable salts, and hydrates thereof, and compositions comprising the same. The invention also relates to methods for treating or preventing a disease or disorder, which comprises administering a therapeutically or prophylactically effective amount a compound described herein.

  本发明涉及一类具有药物活性的杂环化合物及其药物可接受的盐和水合物，以及包含它们的组合物。本发明还涉及一种治疗或预防疾病或障碍的方法，其包括向患者施用本文所述化合物的治疗或预防有效量。
• COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION
  申请人：CERENIS THERAPEUTICS HOLDING SA

  公开号：US20130267554A1

  公开（公告）日：2013-10-10

  The invention relates to classes of pharmaceutically-active heterocyclic compounds and pharmaceutically acceptable salts, and hydrates thereof, and compositions comprising the same. The invention also relates to methods for treating or preventing a disease or disorder, which comprises administering a therapeutically or prophylactically effective amount a compound described herein.

  本发明涉及一类具有药物活性的杂环化合物及其药学上可接受的盐和水合物，以及包含它们的组合物。本发明还涉及一种治疗或预防疾病或障碍的方法，该方法包括向患者施用本文所述化合物的治疗或预防有效量。
• Compounds, compositions and methods useful for cholesterol mobilization
  申请人：Cerenis Therapeutics Holding SA

  公开号：US10220040B2

  公开（公告）日：2019-03-05

  The invention relates to classes of pharmaceutically-active heterocyclic compounds and pharmaceutically acceptable salts, and hydrates thereof, and compositions comprising the same. The invention also relates to methods for treating or preventing a disease or disorder, which comprises administering a therapeutically or prophylactically effective amount a compound described herein.

  本发明涉及一类具有药理活性的杂环化合物及其药学上可接受的盐类和水合物，以及包含这些化合物的组合物。本发明还涉及治疗或预防疾病或紊乱的方法，其中包括施用治疗或预防有效量的本文所述化合物。
• [EN] COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILISATION<br/>[FR] COMPOSÉS, COMPOSITIONS ET MÉTHODES UTILES POUR LA MOBILISATION DU CHOLESTÉROL
  申请人：CERENIS THERAPEUTICS HOLDING SA

  公开号：WO2012054535A3

  公开（公告）日：2012-07-26